Hypersensitivity to phenothiazines. Not for treatment of dementia-related behavioural disturbances. Avoid in patients w/ Parkinson's disease, hypothyroidism, cardiac failure, phaeochromocytoma, myasthenia gravis, prostate hypertrophy, history of narrow angle glaucoma or agranulocytosis (regular monitoring of the complete blood count). Closely monitor patients w/ epilepsy or history of seizures. Discontinue use in the event of unexplained fever, which may be a sign of neuroleptic malignant syndrome. Gradual w/drawal is advisable as acute w/drawal symptoms including nausea, vomiting & insomnia, relapse & extrapyramidal reactions may occur. Response may be delayed in schizophrenia. May potentiate QT interval prolongation, which increases potentially fatal risk of onset for serious ventricular arrythmias of torsades de pointes type; exacerbated QT prolongation in the presence of bradycardia, hypokalaemia & congenital or acquired QT prolongation; perform medical & lab evaluations (eg, biochemical status & ECG) prior to initiation of treatment, if clinical situation permits, to rule out possible risk factors (eg, cardiac disease, family history of QT prolongation; metabolic abnormalities eg, hypokalaemia, hypocalcaemia or hypomagnesemia; starvation; alcohol abuse; concomitant therapy w/ other drugs known to prolong QT interval). Avoid concomitant treatment w/ other neuroleptics. 3-fold increased risk of cerebrovascular events; patients w/ stroke risk factors. Do not use alone where depression is predominant. Avoid exposure to direct sunlight & skin contact of the drug. Avoid in patients w/ liver or renal dysfunction. Pregnancy (3rd trimester) & lactation (suspend breastfeeding during treatment). Lethargy or paradoxical hyperexcitability, tremor & low apgar score may possibly occur in neonates; risk of AR including extrapyramidal &/or w/drawal symptoms w/ varying severity & duration in neonates exposed during the 3rd trimester of pregnancy. Elderly, especially in very hot & cold weather (for risk of hyper- or hypothermia); of whom are susceptible to postural hypotension; increased risk of drug-induced Parkinsonism after prolonged use in the elderly. Not recommended for childn <1 yr or weighing <10 kg; associated w/ dystonic reactions after cumulative 0.5 mg/kg dosage.